Login
uniQure N.V. logo

uniQure N.V.

uniqure.com

What Do They Do?

Develops gene therapy candidates for patients with rare and other serious diseases and licenses global rights to HEMGENIX to CSL Behring.

Who Are Their Customers?

CSL Behring holds exclusive global rights to HEMGENIX, and Genezen supplies the drug directly to CSL Behring under an arrangement made by uniQure.

Do Revenues Turn Into Profits?

No. It lost $199M in FY2025.

Operating income, FY2025
−1151% of revenue
▼ −1% (Loss) vs FY2024 (−$184.3M, −680%)
Net income, FY2025
−1236% of revenue
▲ +17% (Loss) vs FY2024 (−$239.6M, −883%)
Free cash flow, FY2025
−1108% of revenue
▲ +4% (Loss) vs FY2024 (−$186.1M, −686%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +40%
vs $3.7M in Q3 FY2025
Net income
▲ +24% (Loss)
vs −$80.5M in Q3 FY2025
License revenues share of revenue vs 96.8% in Q3 FY2025

HEMGENIX supply The older report says uniQure manufactured HEMGENIX for CSL Behring; the latest says Genezen supplies the drug directly to CSL Behring, with uniQure arranging the supply as an agent.

Pipeline progress The older report placed temporal lobe epilepsy and Fabry gene therapy candidates in preclinical work; the latest describes clinical candidates for MTLE and Fabry disease.

Revenue over time
License revenues Contract manufacturing revenues Collaboration revenues
$1B$500M$0

Who Do They Compete With?

Competes with Novartis, Roche, Wave Life Sciences, Alnylam Pharmaceuticals, Regeneron Pharmaceuticals, Skyhawk Therapeutics, Sarepta Therapeutics, Neurona Therapeutics, EpilepsyGTx, Xenon Pharmaceuticals, Biogen, Ionis Pharmaceuticals, Neurimmune, Coya Therapeutics, Amylyx Pharmaceuticals, NeuroSense Therapeutics, AL-S Pharma, Voyager Therapeutics, Amicus Therapeutics, and Sanofi

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support